article Open AccessTop 1% cited

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Journal of Clinical Oncology · 2008 · Vol. 26(12) · pp. 2013–2019

Leonard B. Saltz✉(CancerCare Manitoba)Stephen Clarke(CancerCare Manitoba)Eduardo Díaz‐Rubio(CancerCare Manitoba)Werner Scheithauer(CancerCare Manitoba)Arié Figer(CancerCare Manitoba)Ralph Wong(CancerCare Manitoba)Sheryl Koski(CancerCare Manitoba)Mikhail Lichinitser(CancerCare Manitoba)Tsai‐Shen Yang(CancerCare Manitoba)Fernando Rivera(CancerCare Manitoba)Félix Couture(CancerCare Manitoba)Florin Sirzén(CancerCare Manitoba)Jim Cassidy(CancerCare Manitoba)

View via DOI Full-text PDF

Abstract

The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC. Overall survival differences did not reach statistical significance, and response rate was not improved by the addition of bevacizumab. Treatment continuation until disease progression may be necessary in order to optimize the contribution of bevacizumab to therapy.

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Gastric Cancer Management and OutcomesBevacizumabMedicineOxaliplatinFOLFOXFolinic acidInternal medicineColorectal cancerOncologyCapecitabineClinical endpoint

MeSH terms

BevacizumabCapecitabineOxaliplatinAdolescentAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsLeucovorinDeoxycytidineDrug Administration ScheduleFemaleFluorouracilHumans

Citations

2,958

FWCI

92.66

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Colorectal cancer statistics, 2017